GlassScriptPhysician profile
Abbass Shafii
NPI 1548218662
$2,355.37
in general payments reported to CMS, 2019-2025
24 companies · $457 in 2025
The $457 reported for 2025 was more than what 77% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2022: $276 · 2023: $504 · 2024: $966 · 2025: $457.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,927.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,927.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $350.05 | 2019-2025 | Xifaxan |
| Janssen Biotech, INC. | $269.23 | 2019-2025 | Stelara, Tremfya, Simponi |
| Gilead Sciences, INC. | $260.13 | 2023-2024 | |
| Abbvie INC. | $216.69 | 2022-2025 | Skyrizi, Rinvoq |
| Lilly USA, LLC | $199.74 | 2023-2025 | Omvoh |
| Celgene Corporation | $150.42 | 2022-2023 | Zeposia |
| Takeda Pharmaceuticals U.S.A., INC. | $117.86 | 2019-2025 | Entyvio |
| Ardelyx, INC. | $107.83 | 2024-2025 | Ibsrela |
| Genzyme Corporation | $105.98 | 2023-2024 | |
| Janssen Scientific Affairs, LLC | $97.90 | 2022 | |
| Intercept Pharmaceuticals, INC. | $69.42 | 2019-2024 | |
| Phathom Pharmaceuticals, INC. | $59.81 | 2025 | Voquezna |
| Qol Medical, LLC | $59.71 | 2024-2025 | Sucraid, Sucraid |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $56.77 | 2023-2024 | Jublia |
| Aimmune Therapeutics, INC. | $55.15 | 2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $28.94 | 2025 | Rezdiffra |
| E.R. Squibb & Sons, L.L.C. | $22.47 | 2024 | Zeposia |
| Ironwood Pharmaceuticals, INC | $22.18 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $20.90 | 2024 | Dupixent |
| Pfizer INC. | $20.75 | 2019 | |
| Novo Nordisk INC | $18.98 | 2025 | Wegovy |
| Conmed Corporation | $17.85 | 2022 | |
| Braintree Laboratories, INC. | $13.42 | 2019 | |
| Medtronic, INC. | $13.19 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Abbass Shafii listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.